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ABSTRACT
Few reviews have been written related to the benefits of supplementing vitamin
C and E in diabetic individuals. Excessive protein glycosylation is seen in persons with
diabetes, and vitamin E and C have been shown to be beneficial in decreasing the
glycosylation of proteins. In addition, vitamins E and Care potent antioxidants and
actively reduce oxidation, triglycerides, and free fatty acid levels in diabetics. Diabetics
may benefit from supplementing vitamins E and C.

INTRODUCTION
Glycoproteins are "molecules composed of covalently joined protein and
carbohydrate" (1 ). There are many different glycoproteins, and in general, they play
roles in the group behavior of cells and other biological functions of the membrane (1).
Nonenzymatic glycosylation of proteins has been documented many times in the
past. The destruction of lysine and the formation of brown colors from excessively
heating, or storing protein with reducing sugars was noted many years ago (2). This
effect is known as the Maillard reaction. A progressive decline in the number of amino
groups of serum albumin was seen when it was.incubated with glucose (2).
Mechanisms are still unclear, but the initial step involves the condensation of an amino
moiety with the aldehyde form of a particular sugar (2). When a glucose is attached to
a phosphate, it exists more often in the aldehyde form, as in glucose-6-phosphate (2).
After the first step, mechanisms become unclear (2).
A glycosylated hemoglobin (HbA 1c) is formed spontaneously in the red blood cell
by a combination of the NH2-terminal amino groups of the hemoglobin

~

chain and

glucose (1 ). The aldehydic portion of the glucose first forms a Schiff base with the NH2

-terminal amino group (see figure 1), which then rearranges to a more stable amino
ketone linkage (see figure 2) by a spontaneous, nonenzymatic reaction (1). "The
a

concentration of HbA 1c is dependent on the concentration of glucose in the blood, and
in prolonged hyperglycemia, it may rise to 12% or more of the total hemoglobin" (1).
HbA 1c levels are useful in following the effectiveness of diabetes treatment in individual
patients. Inhibition of nonenzymatic protein glycosylation could be of great interest to
prevent diabetic complications, including retinopathy, neuropathy, and nephropathy
(3,4).

Figure 1

Figure 2

Devlin TM. Textbook of Biochemistry with Clinical Correlations. Philadelphia, PA: John Wiley and sons; 1986:106.

INHIBITION OF PROTEIN GLYCOSYLATION IN DIABETICS

High HgbA 1c levels, occurring with chronic hyperglycemia may form reactive free
radical intermediates which independently may promote lipid peroxidation (5).
Erythrocytes of diabetic patients have a reduced life span, excessive aggregation,
• altered membrane phospholipid asymmetry and an increased tendency to adhere to
endothelial cells (6). They are also more susceptible to lipid peroxidation than are
erythrocytes of the average population (6). Hyperglycemia and nonenzymatic glycation
increase potential for prooxidant conditions (5). The amount of membrane lipid
peroxidation is directly correlated with HgbA 1c level (6). The mechanism for this is
unknown, but perhaps glucose reduces the molecular oxygen under physiological
conditions, yielding alpha-keto aldehydes, hydrogen peroxide and free radical

intermediates (6). Hydrogen peroxide then produces hydroxyl radicals, and
peroxidative breakdown of phospholipid fatty acids occurs (6).
Oxidative stress may impair the function of enzymes involved in glucose
metabolism (7). Vitamin E, an antioxidant, improves nonoxidative glucose metabolism
in non-insulin-dependent diabetic patients (7). Free radical production can move a
hydrogen atom to a polyunsaturated fatty acid and generate another lipid free radical
and lipohydroperoxide (7). This leads to damage through mechanical disruption of
membranes, decreasing the function of the enzymatic systems, and production of toxic
substances from the disintegration of fatty acids (3). This oxidative stress leads to a
decline in insulin action (7). Vitamin E has a protective role as a free radical scavenger
through a nonenzymatic mechanism outside the cells (7,8). Vitamin E decreases
protein glycosylation, but the mechanism for this occurrence remains uncertain.
Vitamin C may be beneficial in decreasing glycosylation of proteins as well (9).
Vitamin C (dehydroascorbic acid) reacts with amino groups of both amino acids and
proteins (9). Ascorbic acid can compete with glucose for binding to protein, and thereby
can inhibit glycosylation (9). Vitamin C reacts with hemoglobin to produce a charge
change similar to the addition of glucose to hemoglobin (9).
Study One (Ceriello, et al.):
Hypothesis: Vitamin E administration inhibits protein glycosylation in
diabetic subjects.
Methods: Three groups, of 10 insulin-dependant diabetics each, were
matched for duration of disease and metabolic control, one group
received 1200 mg vitamin E, one received 600 mg vitamin E and one
group received a placebo. Plasma glucose and HgbA 1c levels were
monitored.
Results: Fasting labile HgbA 1c and glycosylated proteins decreased
significantly in patients taking vitamin E. The diabetics who received more
vitamin E showed greater reduction. After one month HbA 1c levels were
significantly lowered (see Table 1). Plasma glucoses remained the same.
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Table 1: Ceriello, et al. Diabetes Care;
1991 ;14:68-72

Study Two (Davie, et al.):
Hypothesis: Oral vitamin C supplements inhibit the glycosylation of
proteins, and would be useful in slowing the progression of glycosylated
protein reactions, which increase diabetic complications.
Methods: Twelve healthy volunteers took 1000 mg (1g) of vitamin C daily
for three months. Subjects followed their normal diet patterns. Two
different methods were used to determine whether vitamin C glycosylates
proteins; electrophoresis and affinity chromatography.
Results: A decrease was seen in HgbA 1c with affinity
chromatography (measures the true glycosylated hemoglobin), but it
increased with electrophoresis (measures vitamin C bound to hemoglobin
in addition to the true HgbA1c). The decrease in glycosylated albumin
was twice that of glycosylated hemoglobin, due to structural differences
between the proteins and availability of sites for glycosylation.
IMPROVED INSULIN ACTION IN DIABETICS
Plasma-reduced glutathione (GSH) is a tripeptide found in all cells of higher
animals (1). It is an activator of certain enzymes, and it protects lipids against
autoxidation (1). It can be oxidized to form plasma oxidized glutathione (GSSG) (1).
The ratio of GSSG to GSH may affect beta cell response to glucose (8). An increase in
the GSSG/GSH ratio may lead to increased lipid peroxidation, whereas a decreased
ratio might improve the physical state of plasma membranes and their related activities,
including insulin-mediated glucose transport (8). Orally administered vitamin E
enhances concentrations of GSH in plasma and RBC of humans (8). The GSSG/GSH
ratio decreased after vitamin E administration (900 mg/day) (8). In general, diabetics

have lower plasma vitamin E and total glucose disposal, but higher oxygen production
and plasma GSSG/GSH ratios (8). After supplementing vitamin E, diabetics displayed
a greater reduction in membrane microviscosity, plasma oxygen production, and the
GSSG/GSH ratio (8). An improved insulin sensitivity, consequently leading to greater
inhibition of lipid peroxidation, may explain the significant decline in plasma triglycerides
and free fatty acids (7).
Study Three (Paolisso, et al.):
Hypothesis: Vitamin E improves insulin action in diabetics, inhibits lipid
peroxidation, and decreases plasma triglyceride and free fatty acid levels.
Methods: 20 healthy, elderly subjects took 900 mg vitamin E/day or a
placebo for three months. Plasma glucose, TG, FFA, cholesterol, and
lipoprotein A and B were drawn.
Results: At the end of three months all patients had normal glucosetolerance tests. Vitamin E concentrations rose, and plasma oxygen,
plasma GSSG/GSH and membrane microviscosity all decreased. After
insulin infusion, oxidative and nonoxidative glucose metabolism rose, and
lipid oxidation decreased. Insulin effect on nonoxidative glucose
metabolism was greater after vitamin E administration. Table 2 shows
that plasma TG and FFA concentrations were lowered after vitamin E
administration. No adverse effects were seen with pharmacologic dose of
vitamin E.

Table 2: Paolisso, et al. Am J Clin Nutr. 1994;59:1291-1296.

VITAMIN C: ALDOSE REDUCTASE INHIBITOR

Diabetic hyperglycemia promotes sorbitol production from glucose via aldose
reductase (3). The accumulation of sorbitol, or consequent abnormalities of the polyol
pathway, has been postulated to contribute to progression of chronic diabetic
complications (3). Aldose reductase inhibitors (ARI) decrease the NADPH-dependent

conversion of glucose to sorbitol by aldose reductase enzyme(3). Vitamin C, or
ascorbic acid, is a non-pharmaceutical aldose reductase inhibitor, and may be useful in
decreasing the sorbitol accumulation intracellularly, thereby decreasing diabetic
complications (3). Ascorbic acid, in some cells, is actively transported by a membrane
system that is responsive to insulin (3).

Dehydroascorbate, the oxidized form of

ascorbic acid, competes with glucose for its transport system (3). Vitamin C has low
toxicity and is widely distributed throughout tissues, whereas various pharmaceutical
ARls may be toxic and are not effective in longstanding diabetes (3). Diabetics have
been found to have altered ascorbic acid uptake (3). Diabetics appear to have
problems with absorption of vitamin C, and cellular ascorbic acid status may be
compromised due to slower transport of vitamin C, and diminished concentrations of
vitamin C even when intake is adequate (3). Therefore, supplementing approximately
100 mg of vitamin C per day appears to be beneficial (3).

Study Four (Cunningham, et al.):
Hypothesis: Vitamin C in pharmacologic doses decreases erythrocyte
(RBC) sorbitol, thereby decreasing complications related to diabetes
mellitus.
•
Methods: Vitamin C (ascorbic acid) was given in 100 mg and 600 mg
doses to 58 diabetic and nondiabetic adults to determine its' effectiveness
as an ARI. Control was monitored by fasting plasma glucose,
glycosylated hemoglobin and glycosuria. (Moderate to poor control
throughout the study was seen.) Sorbitol was measured at baseline, 30
and 58 days. Mean HgbA1c (%) was 10.99 in diabetics, and 6.34 in
nondiabetics.
Results: Vitamin C supplementation for 30 days dramatically decreased
RBC sorbitol levels in insulin dependent diabetics, but not in nondiabetics
(See figure 3), and at 58 days 8 of 9 IDDM's were below the upper
erythrocyte sorbitol limit for nondiabetics (16.5 nmol/gHb). Normalization
of RBC sorbitol can be seen when diabetics' intake of vitamin C exceeds
100 mg per day. The level of vitamin C supplementation, at greater than
100 mg per day, did not appear to be a significant factor. Normalization
continued through 2 months after supplementation.
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Figure 3: Cunningham, et al. J American college of Nutrition. 1994; 13:344-350.

CONCLUSION

Vitamin E and C have been shown to be beneficial to diabetics in supplemental
doses. Based on the studies reviewed, 100 mg of vitamin C and 600 mg of vitamin E
daily appear to be useful for decreasing diabetes complications. Vitamin E and C both
play roles in decreasing glycosylation of proteins. Vitamin C decreases sorbitol
formation, and vitamin E increases insulin sensitivity according to the studies reviewed.
In addition they are both powerful antioxidants .. Based on this information,
supplementing may be a useful tool for decreasing diabetes complications. While no
undesirable side effects were seen in any of the subjects taking pharmaceutical doses
of vitamins, studies are still somewhat preliminary. It would be wise to monitor liver and
renal function while taking the supplement.
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